Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Bristol-Myers Extends R&D Deal With Syngene
by Ann M. Thayer
June 9, 2014
| A version of this story appeared in
Volume 92, Issue 23
Bristol-Myers Squibb is extending its drug discovery partnership with Syngene International, a subsidiary of India’s Biocon, for another five years. Since 2007, the companies have worked together on biology, medicinal and process chemistry, analytical research, and drug development at a joint research center in Bangalore. According to BMS, the center has become its largest R&D center outside the U.S., housing more than 400 scientists. The collaboration has already produced six drug candidates.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter